196 related articles for article (PubMed ID: 25327986)
1. Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts.
DiPippo VA; Olson WC; Nguyen HM; Brown LG; Vessella RL; Corey E
Prostate; 2015 Feb; 75(3):303-13. PubMed ID: 25327986
[TBL] [Abstract][Full Text] [Related]
2. Photoimmunotherapy targeting prostate-specific membrane antigen: are antibody fragments as effective as antibodies?
Watanabe R; Hanaoka H; Sato K; Nagaya T; Harada T; Mitsunaga M; Kim I; Paik CH; Wu AM; Choyke PL; Kobayashi H
J Nucl Med; 2015 Jan; 56(1):140-4. PubMed ID: 25500827
[TBL] [Abstract][Full Text] [Related]
3. Targeting prostate cancer cells with a multivalent PSMA inhibitor-guided streptavidin conjugate.
Liu T; Nedrow-Byers JR; Hopkins MR; Wu LY; Lee J; Reilly PT; Berkman CE
Bioorg Med Chem Lett; 2012 Jun; 22(12):3931-4. PubMed ID: 22607680
[TBL] [Abstract][Full Text] [Related]
4. Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor response.
Dela Cruz Chuh J; Go M; Chen Y; Guo J; Rafidi H; Mandikian D; Sun Y; Lin Z; Schneider K; Zhang P; Vij R; Sharpnack D; Chan P; de la Cruz C; Sadowsky J; Seshasayee D; Koerber JT; Pillow TH; Phillips GD; Rowntree RK; Boswell CA; Kozak KR; Polson AG; Polakis P; Yu SF; Dragovich PS; Agard NJ
MAbs; 2021; 13(1):1862452. PubMed ID: 33382956
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer.
Schatz CA; Zitzmann-Kolbe S; Moen I; Klotz M; Nair S; Stargard S; Bjerke RM; Wickstrøm Biseth K; Feng YZ; Indrevoll B; Cruciani V; Karlsson J; Haendler B; Nielsen CH; Alfsen MZ; Hammer S; Hennekes H; Cuthbertson A; Hagemann UB; Larsen Å
Clin Cancer Res; 2024 Jun; 30(11):2531-2544. PubMed ID: 38593212
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Efficacy of the Antibody-Drug Conjugate CLDN6-23-ADC for the Treatment of CLDN6-Positive Solid Tumors.
McDermott MSJ; O'Brien NA; Hoffstrom B; Gong K; Lu M; Zhang J; Luo T; Liang M; Jia W; Hong JJ; Chau K; Davenport S; Xie B; Press MF; Panayiotou R; Handly-Santana A; Brugge JS; Presta L; Glaspy J; Slamon DJ
Clin Cancer Res; 2023 Jun; 29(11):2131-2143. PubMed ID: 36884217
[TBL] [Abstract][Full Text] [Related]
7. Darolutamide Potentiates the Antitumor Efficacy of a PSMA-targeted Thorium-227 Conjugate by a Dual Mode of Action in Prostate Cancer Models.
Hammer S; Schlicker A; Zitzmann-Kolbe S; Baumgart S; Hagemann UB; Scholz A; Haendler B; Lejeune P; Karlsson J; Ellingsen C; Hennekes H; Nielsen CH; Juul MU; Mumberg D; Schatz CA
Clin Cancer Res; 2021 Aug; 27(15):4367-4378. PubMed ID: 34035067
[TBL] [Abstract][Full Text] [Related]
8. ImmunoPET helps predicting the efficacy of antibody-drug conjugates targeting TENB2 and STEAP1.
Williams SP; Ogasawara A; Tinianow JN; Flores JE; Kan D; Lau J; Go M; Vanderbilt AN; Gill HS; Miao L; Goldsmith J; Rubinfeld B; Mao W; Firestein R; Yu SF; Marik J; Terwisscha van Scheltinga AG
Oncotarget; 2016 May; 7(18):25103-12. PubMed ID: 27029064
[TBL] [Abstract][Full Text] [Related]
9. Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigen.
Slovin SF
Expert Opin Ther Targets; 2005 Jun; 9(3):561-70. PubMed ID: 15948673
[TBL] [Abstract][Full Text] [Related]
10. PSMA-targeted dendrimer as an efficient anticancer drug delivery vehicle for prostate cancer.
Dhull A; Wei J; Pulukuri AJ; Rani A; Sharma R; Mesbahi N; Yoon H; Savoy EA; Xaivong Vi S; Goody KJ; Berkman CE; Wu BJ; Sharma A
Nanoscale; 2024 Mar; 16(11):5634-5652. PubMed ID: 38440933
[TBL] [Abstract][Full Text] [Related]
11. Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination.
Gregor PD; Wolchok JD; Turaga V; Latouche JB; Sadelain M; Bacich D; Heston WD; Houghton AN; Scher HI
Int J Cancer; 2005 Sep; 116(3):415-21. PubMed ID: 15800947
[TBL] [Abstract][Full Text] [Related]
12. Prostate-Specific Membrane Antigen-Targeted Site-Directed Antibody-Conjugated Apoferritin Nanovehicle Favorably Influences In Vivo Side Effects of Doxorubicin.
Dostalova S; Polanska H; Svobodova M; Balvan J; Krystofova O; Haddad Y; Krizkova S; Masarik M; Eckschlager T; Stiborova M; Heger Z; Adam V
Sci Rep; 2018 Jun; 8(1):8867. PubMed ID: 29891921
[TBL] [Abstract][Full Text] [Related]
13. PSMA-targeted small-molecule drug-conjugates with valine-citrulline and phosphoramidate cleavable linkers.
Savoy EA; Olatunji FP; Fulton MD; Kesic BN; Herman JW; Romero O; Maniatopoulos M; Berkman CE
Bioorg Med Chem Lett; 2024 Jan; 98():129573. PubMed ID: 38052377
[TBL] [Abstract][Full Text] [Related]
14. Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody-Drug Conjugate for Treatment of CLDN18.2-Positive Cancers.
O'Brien NA; McDermott MSJ; Zhang J; Gong KW; Lu M; Hoffstrom B; Luo T; Ayala R; Chau K; Liang M; Madrid AM; Donahue TR; Glaspy JA; Presta L; Slamon DJ
Mol Cancer Ther; 2023 Dec; 22(12):1365-1375. PubMed ID: 37788341
[TBL] [Abstract][Full Text] [Related]
15. LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics.
Nguyen HM; Vessella RL; Morrissey C; Brown LG; Coleman IM; Higano CS; Mostaghel EA; Zhang X; True LD; Lam HM; Roudier M; Lange PH; Nelson PS; Corey E
Prostate; 2017 May; 77(6):654-671. PubMed ID: 28156002
[TBL] [Abstract][Full Text] [Related]
16. Photoimmunotherapy of Prostate Cancer With Antibody and Fab Fragments Targeting the Prostate Specific Membrane Antigen.
Waibel S; Graf N; Storz J; Schultze-Seemann S; Lauw S; Gratzke C; Brückner R; Wolf P; Wolf I
Anticancer Res; 2024 Jun; 44(6):2343-2348. PubMed ID: 38821609
[TBL] [Abstract][Full Text] [Related]
17. A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors.
Weber JS; Vogelzang NJ; Ernstoff MS; Goodman OB; Cranmer LD; Marshall JL; Miles S; Rosario D; Diamond DC; Qiu Z; Obrocea M; Bot A
J Immunother; 2011 Sep; 34(7):556-67. PubMed ID: 21760528
[TBL] [Abstract][Full Text] [Related]
18. Development and therapeutic evaluation of 5D3(CC-MLN8237)
Liatsou I; Assefa B; Liyanage W; Surasinghe S; Nováková Z; Bařinka C; Gabrielson K; Raman V; Artemov D; Hapuarachchige S
Front Pharmacol; 2024; 15():1385598. PubMed ID: 38751786
[TBL] [Abstract][Full Text] [Related]
19. hIMB1636-MMAE, a Novel TROP2-Targeting Antibody-Drug Conjugate Exerting Potent Antitumor Efficacy in Pancreatic Cancer.
Sun LP; Bai WQ; Zhou DD; Wu XF; Zhang LW; Cui AL; Xie ZH; Gao RJ; Zhen YS; Li ZR; Miao QF
J Med Chem; 2023 Nov; 66(21):14700-14715. PubMed ID: 37883180
[TBL] [Abstract][Full Text] [Related]
20. Development of a MMAE-based antibody-drug conjugate targeting B7-H3 for glioblastoma.
Mao Y; Wei D; Fu F; Wang H; Sun Z; Huang Z; Wang Y; Zhang G; Zhang X; Jiang B; Chen H
Eur J Med Chem; 2023 Sep; 257():115489. PubMed ID: 37235999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]